Entero Therapeutics Appoints New CMO, Director
Ticker: GRDX · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
TL;DR
Entero Therapeutics just hired a new CMO and added a director to the board. Big changes coming?
AI Summary
Entero Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. Jonathan L. Cohen as Chief Medical Officer and the election of Ms. Sarah E. Empey to its Board of Directors. The company also disclosed compensatory arrangements for its officers, though specific dollar amounts for these arrangements were not detailed in this filing.
Why It Matters
Key leadership changes can signal strategic shifts or new directions for a company's medical and governance strategies.
Risk Assessment
Risk Level: medium — Leadership changes and undisclosed compensatory arrangements introduce a degree of uncertainty regarding the company's future direction and financial commitments.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan L. Cohen (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Empey (person) — Elected to Board of Directors
- June 17, 2024 (date) — Date of earliest event reported
FAQ
Who is the new Chief Medical Officer of Entero Therapeutics?
Dr. Jonathan L. Cohen was appointed as the Chief Medical Officer.
Who has been elected to the Board of Directors at Entero Therapeutics?
Ms. Sarah E. Empey has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 17, 2024.
What was Entero Therapeutics, Inc. formerly known as?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc. (since 20210921), AzurRx BioPharma, Inc. (since 20141103), and BioPharma d'Azur, Inc. (since 20140331).
What is the business address of Entero Therapeutics, Inc.?
The business address is 777 Yamato Road, Suite 502, Boca Raton, FL 33431.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-06-20 16:30:18
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Mark
Filing Documents
- tm2417688d1_8k.htm (8-K) — 25KB
- 0001104659-24-073418.txt ( ) — 194KB
- fwbi-20240617.xsd (EX-101.SCH) — 3KB
- fwbi-20240617_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240617_pre.xml (EX-101.PRE) — 22KB
- tm2417688d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 17, 2024, the Board of Directors (the "Board") of Entero Therapeutics, Inc. (the "Company"), after discussions with Jack Syage, the Company's President, Chief Operating Officer and a member of the Board, transitioned Dr. Syage from the role of Chief Operating Officer to the newly appointed role of Chief Scientific Officer, effective immediately. Dr. Syage will continue to serve as the Company's President and report to James Sapirstein, the Company's Chief Executive Officer. Dr. Syage's compensation will not change as a result of the change in position. Information regarding Dr. Syage required by Items 401(b), (d), (e) and item 404(a) of Regulation S-K is hereby incorporated by reference to the Company's revised preliminary proxy
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. June 20, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer